West Pharmaceutical Services (NYSE:WST) Reaches New 52-Week High – Still a Buy?

West Pharmaceutical Services, Inc. (NYSE:WST)’s share price hit a new 52-week high on Monday . The stock traded as high as $367.66 and last traded at $360.9680, with a volume of 546894 shares. The stock had previously closed at $365.74.

Wall Street Analyst Weigh In

WST has been the topic of a number of analyst reports. KeyCorp increased their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Evercore restated an “outperform” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Finally, Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $343.73.

West Pharmaceutical Services Trading Down 1.9%

The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The stock has a market capitalization of $25.35 billion, a P/E ratio of 47.88, a price-to-earnings-growth ratio of 3.06 and a beta of 1.16. The firm’s fifty day simple moving average is $322.63 and its 200 day simple moving average is $278.92.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The company had revenue of $844.90 million during the quarter, compared to the consensus estimate of $779.67 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, equities research analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at $5,135,905.60. This represents a 14.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the sale, the chief accounting officer directly owned 1,523 shares in the company, valued at $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On West Pharmaceutical Services

A number of hedge funds have recently made changes to their positions in the stock. Holocene Advisors LP acquired a new stake in shares of West Pharmaceutical Services during the 3rd quarter valued at $49,085,000. Nordea Investment Management AB raised its position in West Pharmaceutical Services by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier’s stock valued at $4,122,000 after purchasing an additional 4,477 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of West Pharmaceutical Services by 7.7% during the third quarter. JPMorgan Chase & Co. now owns 236,963 shares of the medical instruments supplier’s stock valued at $62,163,000 after purchasing an additional 16,919 shares in the last quarter. Birch Hill Investment Advisors LLC grew its holdings in shares of West Pharmaceutical Services by 11.5% during the fourth quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock worth $41,862,000 after purchasing an additional 15,678 shares during the last quarter. Finally, Brendel Financial Advisors LLC bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth about $3,742,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.